How a big biotech’s start-up gamble went wrong
Behind the Money
Introduction
Francis D'Souza, the CEO of Illumina at the time, spoke on an investor relations call in September 2020. The acquisition valued at $8 billion was presented as a way for Illumina to corner a new market in the realm of cancer screening and detection. PIGIM has over 1,400 investment professionals relentlessly research in pursuit of long-term goals.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
